SLU researchers show how to stop muscle weakness caused by myasthenia gravis
Severe muscle weakness caused by myasthenia gravis a highly debilitating autoimmune disorder can be prevented or reversed by blocking a key step in the immune response that brings on the disease, researchers at the Saint Louis University School of Medicine have found. Myasthenia gravis, which...New Drug Aids Muscle Function in Myasthenia Gravis
Trial of 16 patients saw 46% improvement in symptoms FRIDAY, Aug. 17 (HealthDay News) -- A new drug -- oral EN101antisense -- reduced the severity of muscle weakness in patients with myasthenia gravis, researchers report. Myasthenia gravis (MG), which affects about 20 in 100,000 people, cause...New treatment boosts muscle function in myasthenia gravis
ST. PAUL, Minn. - A new type of treatment significantly reduces the severity of muscle weakness in myasthenia gravis (MG), giving hope for a new class of drugs to treat neurological disorders, according to a study published in the August 14, 2007, issue of Neurology, the medical journal of the Ame...RNA engineering to combat series of illnesses wins Kaye Award for Hebrew University dean
...diseases. EN101, the DNA-based lead compound utilizing this technology, has already been tested on patients with the auto-immune disease myasthenia gravis and has successfully reached phase II clinical trials. The results thus far suggest EN101 may have superior efficacy, longer duration of action, a mor...Blood Cancer Drug Shows Promise Against Lupus
...iated diseases, too, the researchers said. "Autoantibody-mediated diseases such as autoimmune hemolytic anemia, immune thrombocytopenia, myasthenia gravis and systemic lupus erythematosus are often difficult to treat," said lead researcher Dr. Reinhard Voll, of the University of Erlangen-Nuremberg. A...Amarin Regains Compliance With Nasdaq Listing Requirements
...t and commercialization of novel drugs that address unmet patient needs. Amarin's CNS development pipeline includes the recently acquired myasthenia gravis clinical program and preclinical programs in neuromuscular, neuronal degenerative and inflammatory diseases; Miraxion for Huntington's disease; two pr...Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
Results reported in The Journal of Immunology SEATTLE, Feb. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced that pixantrone was shown to reduce the severity of clinical manifestation in the animal model of the autoimmune disease myasthe...AIMSPRO is Awarded TGA Orphan Status for the Treatment of Amyotrophic Lateral Sclerosis
...ce with AIMSPRO, over an extended period, has led Daval to consider Proof of Concept studies in Adhesive Arachnoiditis, treatment resistant Myasthenia gravis and Psoriatic arthritis. AIMSPRO is listed on the Export Only section of the Australian Therapeutic Goods Registry and is imported into Europe ...Myasthenia Gravis Panel (Striated Muscle Antibody, IgG with Reflex to Titer)
Description: ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' client...Researchers map of genetic variations implicated in disease
...about 3 million people in the UK. The three haplotypes studied here display different susceptibilities to diseases such as type 1 diabetes, myasthenia gravis and multiple sclerosis. For some common autoimmune diseases the MHC provides by far the largest genetic contribution by a single chromosome region...Multi-purpose protein regulates new protein synthesis and immune cell development
... unique biochemical reaction. This makes IRE1 a perfect target for pharmacological intervention for B cell-driven autoimmune diseases, like myasthenia gravis or systemic lupus erythematosus." Results from the study will be published in the Feb. 1 issue of the Journal of Clinical Investigation. Kauf...Amarin Secures Global Intellectual Property Rights for Lipid Programs
...t and commercialization of novel drugs that address unmet patient needs. Amarin's CNS development pipeline includes the recently acquired myasthenia gravis clinical program and preclinical programs in neuromuscular, neuronal degenerative and inflammatory diseases; Miraxion for Huntington's disease; two pr...Amarin Appoints Dr. William Mason as Lead Independent Director
...t and commercialization of novel drugs that address unmet patient needs. Amarin's CNS development pipeline includes the recently acquired myasthenia gravis clinical program and preclinical programs in neuromuscular, neuronal degenerative and inflammatory diseases; Miraxion for Huntington's disease; two pr...Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
... Myasthenia - Phase IIa - Conclude Phase gravis IIa ...Amarin's CNS development pipeline includes the recently acquired myasthenia gravis clinical program and preclinical programs in neuromuscular, neuronal degene...Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
...t and commercialization of novel drugs that address unmet patient needs. Amarin's CNS development pipeline includes the recently acquired myasthenia gravis clinical program and preclinical programs in neuromuscular, neuronal degenerative and inflammatory diseases; Miraxion for Huntington's disease; two pr...Amarin Signs Agreement to Acquire Ester Neurosciences
...sing efficacy data for the treatment of myasthenia gravis ("MG") utilising this technology; and (iii) a prec...ancing our Phase II clinical program in myasthenia gravis and further developing our novel technology platfo...website; http://www.amarincorp.com . Myasthenia gravis - An Unmet Medical Need MG is the most common pr...Anti-Acetylcholine Receptor-alpha (AChR-alpha) Monoclonal Antibody, Unconjugated from CHEMICON
Description:...ine receptor (AChR)-alpha. Exhibits homogenous, high affinity binding to the receptor. Binds weakly to a64-78. Inhibits binding of many myasthenia gravis sera to human AChR....